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The clinical and financial burden of non-alcoholic fatty liver disease (NAFLD) is rising, with a 
global prevalence of approximately 25% (1). NAFLD encompasses a wide disease spectrum 
ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. 
The progression to advanced fibrosis occurs in only a small subset of patients, but 
represents a poor prognostic indicator, associated with increased liver-related mortality (2). 
Screening for liver disease severity is therefore vital to appropriately select patients who 
require dedicated hepatological follow-up.  
Although histology remains the gold standard for disease staging (3),  the high prevalence of 
NAFLD and relatively low severity in the majority of patients, makes liver biopsy an 
inappropriate first-line diagnostic tool. In recent years, there has been a rapid surge in the 
development of non-invasive tests for staging of hepatic fibrosis in NAFLD. The strength of a 
non-invasive test for NAFLD lies in its ability to accurately risk-stratify patients, enabling 
improved selection of those requiring secondary care referral or further investigations (4).  
The Fibrosis 4 index (FIB-4) and NAFLD fibrosis score (NFS) are the most commonly used 
simple non-invasive scores for fibrosis assessment in NAFLD and are composed of readily 
available clinical and laboratory variables. They are designed to assess the presence of 
advanced fibrosis (≥F3) and have dual cut-offs, namely a high cut-off with high sensitivity 
and a low cut-off with high specificity. Their main utility is in ruling out advanced fibrosis 
with excellent negative predictive value/likelihood ratio. Therefore, they are increasingly 
being used as early screening tools in patients with NAFLD for the exclusion of advanced 
fibrosis. A meta-analysis of the diagnostic accuracy of non-invasive fibrosis tests in NAFLD, 
incorporating dual cut-off values for FIB-4 and NFS, showed the low cut-off values have 
excellent specificity (0.97 for both FIB-4 and NFS) and the high cut-off values have relatively 
high sensitivity (0.84 for FIB-4, 0.80 for NFS) for ruling out and diagnosing advanced fibrosis 
respectively (5). A proportion of patients falls in an indeterminate category and needs 
further testing. 
Transient elastography (Fibroscan) is the most validated elastography-based technique for 
fibrosis assessment in NAFLD (6). Acoustic Radiation Forced Impulse (ARFI) is an alternative 
elastography technique, which has comparable diagnostic accuracy to Fibroscan for the 
detection of advanced fibrosis and cirrhosis (7). Falsely elevated liver stiffness 
measurements (LSM) can occur in a range of conditions, including acute hepatitis, 
extrahepatic cholestasis, congestive heart failure, hepatic amyloidosis, and recent food 
intake (8). Obesity and the presence of steatosis can also influence diagnostic accuracy, 
prompting the development of a dedicated XL probe for obese patients (9). 
In their study of 315 Asian patients with biopsy-proven NAFLD, Joo and co-authors, 
compared the diagnostic accuracy of a variety of non-invasive tests to detect advanced 
fibrosis and the potential influence of steatosis and other metabolic comorbidities such as 
obesity and the presence of metabolic syndrome. These tests included acoustic radiation 
force impulse imaging (ARFI) to obtain LSM, AST to ALT ratio (AAR), AST to PLT ratio index 
(APRI), FIB-4, NFS and BARD index (Body Mass Index, AST/ALT ratio, Diabetes) (10). 
The cohort in the study included patients with an appropriate spectrum of disease; F1-F2 
and advanced fibrosis (≥F3) were present in 65.4% and 17.4% of patients respectively, while 
steatosis severity was equally distributed with a third of patients having mild, moderate and 
severe steatosis respectively.  
Dual cut-off values were used for FIB-4 and NFS to ‘rule in’ or ‘rule out’ patients with 
advanced fibrosis (10). Comparing the areas under receiver operating characteristic curve 
(AUROC), the authors identified FIB-4 to have the best diagnostic accuracy for ruling out 
advanced fibrosis (NPV 94%, AUROC 0.87). The study confirmed that negative predictive 
values (NPV) of FIB-4, NFS and ARFI were all high, in contrast to relatively modest 
sensitivities and positive predictive values (PPV), therefore these tests appear best placed in 
clinical practice to indicate the absence of advanced fibrosis rather than to diagnose it. As 
already established, NFS and FIB4 were significantly better than APRI, AAR and BARD (11) 
and interestingly they had similar negative predictive values with ARFI (10). 
The severity of radiological steatosis was the only independent factor affecting the AUROC 
of FIB-4 and NFS, while the presence of metabolic syndrome did not significantly affect 
them. Although the AUROC of ARFI numerically decreased with increasing degrees of 
steatosis, this did not reach statistical significance. Importantly, while the sensitivities, 
positive predictive values (PPV) and AUROC of these tests were lower in the context of 
severe steatosis, their NPV were relatively unchanged, permitting their use as screening 
tests for the exclusion of advanced fibrosis. On the other hand, caution is required to avoid 
overestimating positive results and LSM in patients with severe steatosis (10).  
The authors acknowledge several study limitations, including the cross-sectional study 
design and failure to include patented non-invasive direct serum markers of fibrosis such as 
the Enhanced Liver Fibrosis (ELF) panel and FibroTest. The study is also limited to an Asian 
patient population and thus may not be readily applicable to other patient groups.  
The study by Joo showed for the first time that the presence of steatosis affects the 
sensitivity of FIB4 and NFS in patients with NAFLD, and should be taken into account when 
interpreting their results. Perhaps most importantly, steatosis does not affect the specificity 
of NFS and FIB4 and thus their main utility in selecting patients who do not have advanced 
fibrosis. The effect of steatosis follows earlier reports that these scores should be adjusted 
in patients who are above 65 years of age and are unreliable in patients younger than 35 
years (12). Therefore, as with elastography techniques, factors affecting the diagnostic 
accuracy of simple non-invasive tests are increasingly emerging. This key finding is 
summarized in Figure 1. 
This study also confirms the effect of steatosis in LSM measurements as already reported 
with Fibroscan using the M probe; Petta et al. assessed the impact of steatosis severity on 
LSM, in 253 patients with biopsy-proven NAFLD (13). Higher median LSM values, assessed by 
Fibroscan, and a higher rate of false positive LSM results were observed in patients without 
significant fibrosis (F0-F2) who had severe histological or radiological steatosis, indicating an 
overestimation of LSM in this context. A potential explanation is that fat droplets in 
hepatocytes influence the architectural structure of the liver, affecting the propagation time 
of the vibratory wave transmitted by Fibroscan. In patients with advanced fibrosis, the 
specificity of LSM was relatively unchanged despite the presence of severe steatosis, 
supporting the use of Fibroscan as a first-line exclusion tool for advanced fibrosis even in the 
presence of severe steatosis (13). The diagnostic accuracy of ARFI in lesser fibrosis stages 
was not available in this study to corroborate these findings. Incorporating the controlled 
attenuation parameter (CAP) has been suggested as a potential way to overcome the 
influence of steatosis on the diagnostic accuracy of transient elastography. In a study of 324 
patients with NAFLD, higher CAP values were associated with increased rates of false 
positive LSM, determined by the Fibroscan M probe, particularly in patients with lower 
stages of fibrosis (F0-2) (14). It was therefore proposed that combining LSM and CAP values 
may avoid overestimation of liver fibrosis assessed by transient elastography in patients 
with severe steatosis (14). Future studies are required to validate this.  
 
 
In conclusion, the study by Joo confirms the excellent negative predictive value of FIB-4 and 
NFS in ruling out advanced fibrosis in patients with NAFLD, which is not affected by the 
presence of severe steatosis, thus supporting their use as ‘rule out’ tests. However, the rate 
of false positive readings, assessed by simple non-invasive tests or ARFI to a lesser extent, 
does appear to increase in the context of severe steatosis, therefore caution should be 
applied when interpreting results in this patient group. Correcting LSM for the presence of 
steatosis may potentially help to improve diagnostic test accuracy particularly in lesser 
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Figure 1. Pitfalls when using simple non-invasive fibrosis tests in patients with non-alcoholic 
fatty liver disease (NAFLD); the presence of steatosis influences the sensitivity but not the 
specificity of the test. Cut-off adjustment is required if age>65 years. 
